Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.0 %

NYSE BTX opened at $0.21 on Thursday. The company has a 50-day simple moving average of $1.71 and a two-hundred day simple moving average of $1.96. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The firm has a market cap of $12.07 million, a price-to-earnings ratio of -0.56 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.